In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: Current status on methodologies and their utility for predicting drug-drug interactions

AAPS Journal

Volumn 10, Issue 2, 2008, Pages 410-424

  Fowler, Stephen ^a   Zhang, Hongjian ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cytochrome P450 (CYP); Drug interactions; Time dependent inhibition

Indexed keywords

ALPHA NAPHTHOFLAVONE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; KETOCONAZOLE; MIDAZOLAM;

DRUG CLEARANCE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; FLUORESCENCE ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; INHIBITION KINETICS; LIQUID CHROMATOGRAPHY; METHODOLOGY; MICHAELIS MENTEN KINETICS; NONHUMAN; POLYPHARMACY; PREDICTION; PROTEIN CONTENT; RADIOMETRY; REVIEW; TANDEM MASS SPECTROMETRY;

CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; MICROSOMES, LIVER; SUBSTRATE SPECIFICITY;

EID: 53849084442     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-008-9042-7     Document Type: Review

References (67)

1. A. D. Rodrigues (ed.). In Drug-Drug Interactions. Drugs and the Pharmaceutical Sciences, 116. Marcel Dekker, New York, 2002.
2. FDA. Guidance for Industry: Drug interaction studies-study design, data analysis and implications for dosing and labelling. Available at: http://www.fda.gov/cder/guidance/index.htm.
3. O. V. Trubetskoy, J. R. Gibson, and B. D. Marks. Highly miniaturized formats for in vitro drug metabolism assays using Vivid fluorescent substrates and recombinant human cytochrome P450 enzymes. J. Biomol. Screen. 10 (1):56-66 (2005).
4. C. L. Crespi, V. P. Miller, and D. M. Stresser. Design and Application of Fluorogenic Assays for Human Cytochrome P450 Inhibition. In E. F. Johnson, and M. R. Waterman (eds.), Cytochrome P450, Part C. Vol 357, Academic Press, London, 2002.
5. J. J. Cali, D. Ma M. Sobol et al. Luminogenic cytochrome P450 assays. Expert Opin. Drug Metab. Toxicol. 2 (4):629-645 (2006).
6. A. Di Marco, I. Marcucci M. Verdirame et al. Development and validation of a high-throughput radiometric CYP3A4/5 inhibition assay using tritiated testosterone. Drug Metab. Dispos. 33 (3):349-358 (2005).
7. A. Di Marco, A. Cellucci, A. Chaudhary, M. Fonsi, and R. Laufer. High-throughput radiometric CYP2C19 inhibition assay using tritiated (S)-mephenytoin. Drug Metab. Dispos. 35 (10):1737-1743 (2007).
8. G. C. Moody, S. J. Griffin, A. N. Mather, D. F. McGinnity, and R. J. Riley. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: Assessment of human CYP inhibition potential. Xenobiotica. 29 (1):53-75 (1999).
9. R. L. Walsky, and R. S. Obach. Validated assays for human cytochrome P450 activities. Drug Metab. Dispos. 32 (6):647-660 (2004).
10. R. Weaver, K. S. Graham, I. G. Beattie, and R. J. Riley. Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab. Dispos. 31 (7):955-966 (2003).
11. E. A. Dierks, K. R. Stams, H. K. Lim, G. Cornelius, H. Zhang, and S. E. Ball. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab. Dispos. 29 (1):23-29 (2001).
12. R. L. Walsky, A. V. Astuccio, and R. S. Obach. Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J. Clin. Pharmacol. 46 (12):1426-1438 (2006).
13. R. L. Walsky, E. A. Gaman, and R. S. Obach. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J. Clin. Pharmacol. 45 (1):68-78 (2005).
14. M. Shou. Kinetic Analysis for Multiple Substrate Interaction at the Active Site of Cytochrome P450. In E. F. Johnson, and M. R. Waterman (eds.), Cytochrome P450 Part C. Vol 357, 1st edn, Academic Press, New York, 2002, pp. 261-276.
15. M. Shou, Y. Lin P. Lu et al. Enzyme kinetics of cytochrome P450-mediated reactions. Current Drug Metabolism. 2 (1):17-36 (2001).
16. J. B. Houston, and A. Galetin. Modelling atypical CYP3A4 kinetics: Principles and pragmatism. Arch. Biochem. Biophys. 433 (2):351-360 (2005).
17. J. B. Houston, and K. E. Kenworthy. In vitro - in vivo scaling of cyp kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab. Dispos. 28 (3):246-254 (2000).
18. J. M. Hutzler, and T. S. Tracy. Atypical kinetic profiles in drug metabolism reactions. Drug Metab. Dispos. 30 (4):355-362 (2002).
19. W. M. Atkins. Current views on the fundamental mechanisms of cytochrome P450 allosterism. Expert Opin. Drug Metab. Toxicol. 2 (4):573-579 (2006).
20. W. F. Busby, J. M. Ackermann, and C. L. Crespi. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab. Dispos. 27 (2):246-249 (1999).
21. R. Vuppugalla, S. Y. Chang, H. Zhang, P. H. Marathe, and D. A. Rodrigues. Effect of commonly used organic solvents on the kinetics of cytochrome P450 2B6- and 2C8-dependent activity in human liver microsomes. Drug Metab. Dispos. 35 (11):1990-1995 (2007).
22. R. P. Austin, P. Barton, S. L. Cockroft, M. C. Wenlock, and R. J. Riley. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab. Dispos. 30 (12):1497-1503 (2002).
23. D. Hallifax, and J. B. Houston. Binding of drugs to hepatic microsomes: Comment and assessment of current prediction methodology with recommendation for improvement (1). Drug Metab. Dispos. 34 (4):724-726 (2006).
24. L. Di, E. H. Kerns, S. Q. Li, and G. T. Carter. Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS. Int. J. Pharm. 335 (1-2):1-11 (2007).
25. F. Gao, D. L. Johnson S. Ekins et al. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50). J. Biomol. Screen. 7 (4):373-382 (2002).
26. J. B. Houston, K. E. Kenworthy, and A. Galetin. Typical and atypical kinetics. In J. S. Lee, R. S. Obach, and M. B. Fisher (eds.), Drug Metabolising Enzymes, Marcel Dekker, New York, 2002, pp. 211-254.
27. R. B. Silverman. Mechanism-based Enzyme Inactivation: Chemistry and Enzymology. Vol 1, CRC Press, Boca Raton, 1988.
28. B. Ma, T. Prueksaritanont, and J. H. Lin. Drug interactions with calcium channel blockers: Possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab. Dispos. 28 (2):125-130 (2000).
29. X. J. Zhao, D. R. Jones, Y.-H. Wang, S. W. Grimm, and S. D. Hall. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica. 32 (10):863-878 (2002).
30. S. Zhou, S. Y. Chan B. C. Goh et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44 (3):279-304 (2005).
31. A. S. Kalgutkar, R. S. Obach, and T. S. Maurer. Mechanism-based inactivation of cytochrome P450 enzymes: Chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Current Drug Metabolism. 8 (5):407-447 (2007).
32. F. P. Guengerich. Cytochrome P450 oxidations in the generation of reactive electrophiles: Epoxidation and related reactions. Arch. Biochem. Biophys. 409: 59-71 (2003).
33. R. S. Obach, R. L. Walsky, and K. Venkatakrishnan. Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos. 35 (2):246-255 (2007).
34. D. A. Fairman, C. Collins, and S. Chapple. Progress curve analysis of CYP1A2 inhibition: A more informative approach to the assessment of mechanism-based inactivation? Drug Metab. Dispos. 35 (12):2159-2165 (2007).
35. R. B. Silverman. Mechanism-based enzyme inactivators. In D. L. Purich (ed.), Enzyme Kinetics and Mechanism. Part D: Developments in Enzyme Dynamics. Vol 249, Academic Press, New York, 1995, pp. 240-283.
36. F. Ghanbari, K. Rowland-Yeo J. C. Bloomer et al. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro - in vivo extrapolation. Current Drug Metabolism. 7 (3):315-334 (2006).
37. R. L. Walsky, R. S. Obach, E. A. Gaman, J. P. R. Gleeson, and W. R. Proctor. Selective inhibition of humam cytochrome P4502C8 by montelukast. Drug Metab. Dispos. 33 (3):413-418 (2005).
38. K. E. Kenworthy, J. C. Bloomer, S. E. Clarke, and J. B. Houston. CYP3A4 drug interactions: Correlation of 10 in vitro probe substrates. BJCP, Br. J. Clin. Pharmacol. 48 (5):716-727 (1999).
39. J. K. Yano, M. R. Wester, G. A. Schoch, K. J. Griffin, C. D. Stout, and E. F. Johnson. The structure of human microsomal cytochrome P450 3A4 determined by X- ray crystallography to 2.05-A resolution. J. Biol. Chem. 279 (37):38091-38094 (2004).
40. K. K. Chohan, S. W. Paine, and N. J. Waters. Quantitative structure activity relationships in drug metabolism. Current Topics in Medicinal Chemistry. 6 (15):1569-1578 (2006).
41. R. Arimoto. Computational models for predicting interactions with cytochrome p450 enzyme. Current Topics in Medicinal Chemistry. 6 (15):1609-1618 (2006).
42. D. A. Smith, M. J. Ackland, and B. C. Jones. Properties of cytochrome P450 isoenzymes and their substrates. Part 2: Properties of cytochrome P450 substrates. Drug Discov. Today. 2 (11):479-486 (1997).
43. M. Rowland, and T. N. Tozer. Clinical Pharmacokinetics: Concepts and Applications, 3rd edn, Lippincott Williams and Wilkins, Philadelphia, 1995.
44. R. S. Obach, R. L. Walsky, K. Venkatakrishnan, E. A. Gaman, J. B. Houston, and L. M. Tremaine. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J. Pharmacol. Exp. Ther. 316 (1):336-348 (2006).
45. A. Galetin, H. Burt, L. Gibbons, and J. B. Houston. Prediction of time-dependent CYP3A4 drug-drug interactions: Impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab. Dispos. 34 (1):166-175 (2006).
46. C. Lu, G. T. Miwa, R. P. Shimoga, L. S. Gan, and S. K. Balani. A novel method for the prediction of drug-drug interactions in humans based on in vitro cytochrome P450 phenotypic data. Drug Metab. Dispos. 35 (1):79-85 (2007).
47. K. Ito, T. Iwatsubo, S. Kanamitsu, K. Ueda, H. Suzuki, and Y. Sugiyama. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver. Pharmacol. Rev. 50 (3):387-411 (1998).
48. J. Y. Chien, A. Lucksiri, I. C. S. Ernest, J. C. Gorski, S. A. Wrighton, and S. D. Hall. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab. Dispos. 34 (7):1208-1219 (2006).
49. K. Ito, H. S. Brown, and J. B. Houston. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br. J. Clin. Pharmacol. 57 (4):473-486 (2004).
50. S. I. Kanamitsu, K. Ito, and Y. Sugiyama. Quantitative prediction of in vivo drug-Drug interactions from in vitro data based on physiological pharmacokinetics: Use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm. Res. 17 (3):336-343 (2000).
51. H. S. Brown, K. Ito, A. Galetin, and J. B. Houston. Prediction of in vivo drug-drug interactions from in vitro data: Impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br. J. Clin. Pharmacol. 60 (5):508-518 (2005).
52. Y.-H. Wang, D. R. Jones, and S. D. Hall. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab. Dispos. 32 (2):259-266 (2004).
53. K. Ito, D. Hallifax, R. S. Obach, and J. B. Houston. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab. Dispos. 33 (6):837-844 (2005).
54. T. M. Polasek, and J. O. Miners. In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opin. Drug Metab. Toxicol. 3 (3):321-329 (2007).
55. J. Wu, C. S. Hughes P. Picard et al. High-throughput cytochrome P450 inhibition assays using laser diode thermal desorption-atmospheric pressure chemical ionization-tandem mass spectrometry. Anal. Chem. 79 (12):4657-4665 (2007).
56. P. H. Marathe, and A. D. Rodrigues. In vivo animal models for investigating potential CYP3A- and Pgp- mediated drug-drug interactions. Current Drug Metabolism. 7 (7):687-704 (2006).
57. T. Kanazu, Y. Yamaguchi, N. Okamura, T. Baba, and M. Koike. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: Establishment and evaluation of dexamethasone- pretreated female rats. Xenobiotica. 34 (5):403-413 (2004).
58. S. N. Umathe, P. V. Dixit, V. kumar, K.U. Bansod, and M. M. Wanjari. Quercetin pretreatment increases the bioavailability of pioglitazone in rats: Involvement of CYP3A inhibition. Biochem. Pharmacol. 75 (8):1670-1676 (2008).
59. S. V. Mandlekar, A. V. Rose G. Cornelius et al. Development of an in vivo rat screen model to predict pharmacokinetic interactions of CYP3A4 substrates. Xenobiotica. 37 (9):923-942 (2007).
60. W. Muck. Clinical pharmacokinetics of cerivastatin. Clin. Pharmacokinet. 39 (2):99-116 (2000).
61. B. Roca, B. Calvo, and R. Monferrer. Severe rhabdomyolysis and cerivastafin-gemfibrozil combination therapy (2). Ann. Pharmacother. 36 (4):730-731 (2002).
62. J.T. Backman, C. Kyrklund, M. Neuvonen, and P. J. Neuvonen. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. 72 (6):685-691 (2002).
63. B. W. Ogilvie, D. Zhang W. Li et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug-drug interactions. Drug Metab. Dispos. 34 (1):191-197 (2006).
64. Y. Shitara, M. Hirano, H. Sato, and Y. Sugiyama. Gemfibrozil and its glucoronide inhibit the organic anion transporting polypeptide 2 (OATP2/ OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 311 (1):228-236 (2004).
65. R. J. Riley, K. Grime, and R. Weaver. Time-dependent CYP inhibition. Expert Opin. Drug Metab. Toxicol. 3 (1):51-66 (2007).
66. E. M. Howgate, K. Rowland-Yeo, N. J. Proctor, G. T. Tucker, and A. Rostami-Hodjegan. Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability. Xenobiotica. 36 (6):473-497 (2006).
67. A. Rostami-Hodjegan, and G. Tucker. 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discov. Today: Technol. 1 (4):441-448 (2004).